^
    Back
    Association details:
    Biomarker:AXL expression
    Cancer:Melanoma
    Drug:Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    PLoS One
    Title:

    Soluble AXL as a marker of disease progression and survival in melanoma

    Excerpt:
    Additionally, increased sAXL levels were found correlated with shorter two-year survival in stage IV patients treated with ipilimumab. Furthermore, we showed that sAXL levels were related to the percentage of cells expressing AXL in resected melanoma lymph node metastases.
    DOI:
    10.1371/journal.pone.0227187